Drug Trial Radar · NCT06897839
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
366
Planned (sponsor's estimate)
Start
Feb 3, 2025
Primary completion
Mar 31, 2028
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Airway Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 minutes, up to 96 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design. The goal fo this study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in extremely premature babies. The study comprises 2 parts: * Part 1: Phase 2b, dose selection and exploratory efficacy and safety. * Part 2: Phase 3, confirmatory efficacy and safety. In Part 1, the study subjects will be randomized with a 1:1:1 allocation ratio to either : 1. Standard of care + zelpultide alfa 4 mg/kg or, 2. Standard of care + zelpultide alfa 6 mg/kg or, 3. Standard of care + placebo (air-sham). In Part 1, all three arms will be evaluated descriptively to support dose selection based on safety, tolerability, and exploratory efficacy signals. Upon completion of Part 1, the DSMC will recommend which Phase 2b dose ("selected dose") to progress into Part 2 to the Study Steering Committee, which will decide the dose for Part 2 (Phase 3). A sample size reassessment will be performed after Part 1 completion. In Part 2, the selected dose of zelpultide alfa will be compared against placebo (air-sham) in a confirmatory analysis on the primary and key secondary endpoints. The study subjects will be randomized with a 1:1 allocation ratio to either: 1. Standard of care + zelpultide alfa (selected dose from Part 1), or 2. Standard of care + placebo (air-sham). The main objective in part 2 is to compare the efficacy of zelpultide alfa added to standard of care versus standard of care plus placebo (air-sham) in terms of incidence of grade 2 and grade 3 bronchopulmonary dysplasia (BPD) and death in neonates at high risk for developing BPD. In both parts, treatment will be administered intratracheally. Participants will receive up to 7 administrations of zelpultide alfa at (4mg/kg or 6 mg/kg) or air-sham in 24 h intervals while the subjects are still intubated per standard of care.
Conditions
- Bronchopulmonary Dysplasia
Interventions
Air-shamOther
Room air for intratracheal administration
Zelpultide alfaDrug
Reconstituted Zelpultide alfa for intratracheal administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or deathTime frame: Week 36 Post Menstrual Age (PMA)
Locations
56 sites in 10 countries. Site status is shown where the registry gives one.
Clínica y Maternidad Suizo Argentina
Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina · Recruiting
Hospital Sanatorio de la Trinidad San Isidro
Buenos Aires, Argentina · Recruiting
Hospital Universitario Austral
Buenos Aires, Argentina · Recruiting
ZAS Middelheim
Antwerp, Belgium · Recruiting
UZ Brussels
Brussels, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
CHU de Liege - Hospital de la Citadelle
Liège, Belgium · Recruiting
Clinique CHC MontLégia
Liège, Belgium · Recruiting
Institute for the Care of Mother and Child
Prague, Czechia · Not yet recruiting
Tomas Bata Regional Hospital in Zlin
Zlín, Czechia · Not yet recruiting
CHU Lille - Hôpital Jeanne de Flandre
Lille, France · Recruiting
CHRU Nancy
Nancy, France · Recruiting
CHU Nice
Nice, France · Recruiting
AP-HP CHU Robert-Debré - Hôpitaux de Paris
Paris, France · Recruiting
AP-HP Paris Saclay University - Hôpitaux Antoine-Béclère
Paris, France · Recruiting
AP-HP Paris Saclay University Bicêtre Hospital
Paris, France · Recruiting
AP-HP University Hospital Cochin - Port Royal
Paris, France · Recruiting
Hôpital de Poissy Saint-Germain-en-Laye
Poissy, France · Recruiting
Medical Faculty of TU Dresden
Dresden, Germany · Not yet recruiting
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany · Recruiting
Heidelberg University Hospital
Heidelberg, Germany · Not yet recruiting
Klinikum Nürnberg
Nuremberg, Germany · Not yet recruiting
University Children's Hospital Regensburg (KUNO)
Regensburg, Germany · Recruiting
University Hospital Würzburg
Würzburg, Germany · Recruiting
Bnai Zion Medical Center
Haifa, Israel · Recruiting
Rambam Medical Center
Haifa, Israel · Recruiting
Haddasah medical center
Jerusalem, Israel · Recruiting
Shaare-Zedek Medical Center
Jerusalem, Israel · Recruiting
Ziv Medical Center
Safed, Israel · Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Bologna, Italy · Recruiting
Istituto Giannina Gaslini
Genova, Italy · Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy · Recruiting
Ospedale dei Bambini "V. Buzzi"
Milan, Italy · Recruiting
Università degli Studi di Napoli Federico II
Naples, Italy · Recruiting
Azienda Ospedale Università di Padova
Padova, Italy · Recruiting
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland · Recruiting
University Hospital in Krakow
Krakow, Poland · Recruiting
Polish Mother's Memorial Hospital - Research Institute in Lodz
Lodz, Poland · Recruiting
Gynecological Obstetric Clinical Hospital of Poznan University of Medical Sciences
Poznan, Poland · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.